title: Rofecoxib, Merck, and the FDA.
authors.forename: Peter S
authors.initials: PS
authors.lastname: Kim
authors.forename: Alise S
authors.initials: AS
authors.lastname: Reicin
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000266:history; D017277:Drug Approval / Q000266:history*; D004345:Drug Industry / Q000266:history*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000266:history; D016032:Randomized Controlled Trials as Topic / Q000266:history; D013450:Sulfones / Q000009:adverse effects* / Q000266:history; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib